We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breath-Based Sampling System Diagnoses Lower Respiratory Tract Infection

By LabMedica International staff writers
Posted on 26 Sep 2024
Print article
Image: BreathBiomics is a novel mechanism to capture biomolecules in human breath (Photo courtesy of ZeteoTech)
Image: BreathBiomics is a novel mechanism to capture biomolecules in human breath (Photo courtesy of ZeteoTech)

Lower Respiratory Tract Infections (LRTIs) are the leading cause of death from infectious diseases. Current diagnostic methods rely heavily on clinical symptoms but often lack specificity, particularly given the prevalence of bacterial colonization without active infection. The use of human breath for noninvasive disease detection has long been recognized as a promising diagnostic tool, but the absence of effective biomolecular sampling technologies has limited progress. To overcome this challenge, a new sampling system has been developed to efficiently capture biomolecules from human breath. This system targets protease dysregulation, a known indicator of bacterial infections, by capturing proteases and enabling their activity-based detection, thus aiding in the diagnosis of LRTIs.

ZeteoTech’s (Sykesville, MD, USA) BreathBiomics sampling system introduces an innovative capture mechanism that utilizes advanced surface chemistry to collect non-volatile organic compounds from exhaled breath. The system features chemically modified functional groups designed to have a high affinity for a broad spectrum of biomolecules, including lipids, metabolites, and proteins, allowing for a comprehensive analysis of respiratory health. By leveraging molecular interactions, the system effectively captures biomolecules contained in submicron particles, addressing a significant limitation of existing collection technologies. Additionally, the functional groups can be customized to target specific biomarkers, such as those associated with SARS-CoV-2, offering enhanced flexibility for biomarker detection and diagnosis.

The BreathBiomics sampling system is highly adaptable, integrating seamlessly into various respiratory devices such as facial masks, mouthpieces, mechanical ventilators, oxygen masks, incubators, and tracheostomy tubes. Its quiet operation, generating noise levels below 45 dB (similar to a home refrigerator), makes it ideal for use in clinical environments, including primary care settings, emergency rooms, operating rooms, and intensive care units. Whether used for clinical research or routine care, BreathBiomics has the potential to revolutionize the way clinicians detect and manage respiratory diseases.

Related Links:
ZeteoTech

New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.